Post-transplantation Cyclophosphamide-based Graft-versus-Host Disease Prophylaxis
Recommended
Post-transplantation Cyclophosphamide-based Graft-versus-Host Disease Prophylaxis
In this phase 3 trial, study investigators randomly assigned adults with hematologic cancers on a 1-to-1 basis to receive cyclophosphamide–tacrolimus–mycophenolate mofetil (experimental prophylaxis) or tacrolimus–methotrexate (standard prophylaxis).
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->